FDA risk alert highlights Owlet’s competitive moat, says Northland

Noting that the FDA issued a communication on September 16 to warn consumers, caregivers, and health care providers of the risks related to using unauthorized infant monitors for measuring and monitoring vital signs, Northland pointed out that Owlet’s (OWLT) Dream Sock is the first and only OTC FDA approved infant monitoring device on the market. The firm, which contends that the FDA alert of risks displays Owlet’s competitive moat in the market, keeps an Outperform rating and $12 price target on Owlet shares.